Revenue
2024
2025
BioAge Labs, Inc. (BIOA)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $9.0M | $0 | — |
| Research & development | $74.0M | $59.0M | $33.9M |
| Operating expenses | $101.8M | $78.2M | $48.4M |
| Operating income | −$92.8M | −$78.2M | −$48.4M |
| Net income | −$80.6M | −$71.1M | −$63.9M |
| Basic EPSper diluted share | -$2.24 | -$6.63 | -$38.17 |
| Diluted EPSper diluted share | -$2.24 | -$6.63 | -$38.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 1, 2026Form 4 · 10b5-1 | RUBIN PAUL DChief Medical Officer | SellCommon Stock | 8.8K | $17.81 | $157.1K | 0 |
| Mar 2, 2026Form 4 · 10b5-1 | RUBIN PAUL DChief Medical Officer | SellCommon Stock | 7.4K | $20.30 | $150.9K | 0 |
| Feb 2, 2026Form 4 · 10b5-1 | RUBIN PAUL DChief Medical Officer | SellCommon Stock | 7.4K | $18.75 | $139.4K | 0 |
| Jan 13, 2026Form 4 · 10b5-1 | Fortney KristenChief Executive Officer | SellCommon Stock | 233.1K | $18.12 | $4.22M | 976.9K |
| Jan 13, 2026Form 4 · 10b5-1 | GOLDSTEIN DOV A MDChief Financial Officer | SellCommon Stock | 1.9K | $21.08 | $40.5K | 22.4K |